Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Cheng is a Cardiologist at Stanford University School of Medicine in the Department of Medicine and a member of the Cardiovascular Research Institute. Dr. Cheng received his BEng in Chemical Engineering and BSc in biology at MIT. He subsequently completed his MD/PhD at UCSF working in the Srivastava lab studying how extracellular morphogenic signals affect cardiac development and fate determination of cardiac progenitors. Dr. Cheng completed internal medicine residency and cardiology fellowship at Stanford. His current clinical focus is in amyloidosis and cardio-oncology. During his post doctoral research in the Quertermous lab, he pioneered the application of single cell transcriptomic and epigenetic techniques to study human vascular diseases including atherosclerosis and aneurysm, and applied these techniques to investigate molecular mechanisms behind genetic risk factors for several human vascular diseases including atherosclerosis, and aortopathies such as Marfan's and Loey-Dietz syndrome.
The Cheng lab takes a patient-to-bench-to-bedside approach to science. The lab focuses on elucidating new pathogenic mechanisms of human vascular diseases through combing human genetics and primary vascular disease tissues, with high-resolution transcriptomic and epigenetic profiling to generate novel hypothesis that are then tested in a variety of in vitro and in vivo models. The lab is focused on two broad questions: (1) understanding the biological underpinning of the differences in diseases propensities of different arterial segments in an individual (i.e. why do you have atherosclerosis and aneurysms in certain segments but not others), and (2) understanding the role of perivascular fibroblast in human vascular diseases.
The Cheng lab takes a patient-to-bench-to-bedside approach to science. The lab focuses on elucidating new pathogenic mechanisms of human vascular diseases through combing human genetics and primary vascular disease tissues, with high-resolution transcriptomic and epigenetic profiling to generate novel hypothesis that are then tested in a variety of in vitro and in vivo models. The lab is focused on two broad questions: (1) understanding the biological underpinning of the differences in diseases propensities of different arterial segments in an individual (i.e. why do you have atherosclerosis and aneurysms in certain segments but not others), and (2) understanding the role of perivascular fibroblast in human vascular diseases.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Cardiovascular Disease (2020)
- Board Certification, American Board of Internal Medicine - Cardiovascular Medicine, Cardiovascular Medicine/Cardiology (2021)
- Fellowship: Stanford University Cardiovascular Medicine Fellowship (2020) CA
- Board Certification: American Board of Internal Medicine, Internal Medicine (2017)
- Residency: Stanford University Internal Medicine Residency (2016) CA
- Medical Education: University of California at San Francisco School of Medicine (2014) CA
- Fellow, Cardiology (2020)
- Resident, Stanford Internal Medicine (2016)
- MD, PhD, University of California, San Francisco (2014)
Honors & Awards
- AHA Career Development Award, American Heart Association (1/2021-1/2024)
- Gerald Reaven Award for Basic Science, Stanford University Dept of Internal Medicine (2019)
- K08 NIH Career Development Award, NIH/NHLBI (8/2020-7/2025)
- Louis N. and Arnold M. Katz Basic Research Prize, American Heart Association (11/2021)
- Ruth L. Kirschtein NRSA NIH Postdoctoral Fellowship (F32), NIH / NHLBI (2018-2020)
- Timothy F. Beckett, Jr. Award for Excellence in Teaching by a Medicine Fellow, Stanford Univ. Dept. of Internal Medicine (2017)
Publications
-
Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: Molecular convergence with single-domain camelid and shark antibodies
Lipovsek, D., Lippow, S. M., Hackel, B. J., Gregson, M. W., Cheng, P., Kapila, A., & Wittrup, K. D. (2007). Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: Molecular convergence with single-domain camelid and shark antibodies. JOURNAL OF MOLECULAR BIOLOGY, 368(4), 1024–41. -
YTIC Lymphohistiocytosis (HLH) in Adult Recipients of Ventricular Assist Devices (VADS) for Cardiomyopathy (CM) and Favorable Outcomes in Subsequent Orthotopic Heart Transplantation (OHT)
Martin, B. A., Cheng, P., Ha-Tien, R., & Banerjee, D. (2016). YTIC Lymphohistiocytosis (HLH) in Adult Recipients of Ventricular Assist Devices (VADS) for Cardiomyopathy (CM) and Favorable Outcomes in Subsequent Orthotopic Heart Transplantation (OHT). PEDIATRIC BLOOD & CANCER. WILEY-BLACKWELL. -
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS ASSOCIATED WITH IMPLANTATION OF VENTRICULAR ASSIST DEVICES AND OUTCOMES FOLLOWING SUBSEQUENT ORTHOTROPIC HEART TRANSPLANTATION (OHT)
Cheng, P., Davis, M., Ha, R., Martin, B., & Banerjee, D. (2017). HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS ASSOCIATED WITH IMPLANTATION OF VENTRICULAR ASSIST DEVICES AND OUTCOMES FOLLOWING SUBSEQUENT ORTHOTROPIC HEART TRANSPLANTATION (OHT). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC. -
What's in a Name? Factors That Influence the Usage of Generic Versus Trade Names for Cardiac Medications Among Healthcare Providers
Ouyang, D., Tisdale, R., Cheng, P., Chi, J., Chen, J. H., & Ashley, E. (2018). What's in a Name? Factors That Influence the Usage of Generic Versus Trade Names for Cardiac Medications Among Healthcare Providers. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 11(8). -
Persistent Fever Can be Associated with Transient but Severe Hemophagocytic Lymphohistiocytosis (HLH) in Adult Recipients of Ventricular Assist Devices (VAD) for Treatment of Cardiomyopathy (CM)
Martin, B. A., Cheng, P. A., Banerjee, D., & Ha, R.-T. (2016). Persistent Fever Can be Associated with Transient but Severe Hemophagocytic Lymphohistiocytosis (HLH) in Adult Recipients of Ventricular Assist Devices (VAD) for Treatment of Cardiomyopathy (CM). BLOOD. AMER SOC HEMATOLOGY. -
Coronary artery disease genes SMAD3 and TCF21 promote opposing interactive genetic programs that regulate smooth muscle cell differentiation and disease risk.
Iyer, D., Zhao, Q., Wirka, R., Naravane, A., Nguyen, T., Liu, B., … Quertermous, T. (2018). Coronary artery disease genes SMAD3 and TCF21 promote opposing interactive genetic programs that regulate smooth muscle cell differentiation and disease risk. PLoS Genetics, 14(10), e1007681. -
TCF21 and AP-1 interact through epigenetic modifications to regulate coronary artery disease gene expression
Zhao, Q., Wirka, R., Trieu Nguyen, Nagao, M., Cheng, P., Miller, C. L., … Quertermous, T. (2019). TCF21 and AP-1 interact through epigenetic modifications to regulate coronary artery disease gene expression. GENOME MEDICINE, 11. -
Coronary artery disease genes SMAD3 and TCF21 promote opposing interactive genetic programs that regulate smooth muscle cell differentiation and disease risk
Iyer, D., Zhao, Q., Wirka, R., Naravane, A., Trieu Nguyen, Liu, B., … Quertermous, T. (2018). Coronary artery disease genes SMAD3 and TCF21 promote opposing interactive genetic programs that regulate smooth muscle cell differentiation and disease risk. PLOS GENETICS, 14(10). -
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation.
Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., … Turakhia, M. P. (2019). Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. The New England Journal of Medicine, 381(20), 1909–17. -
A regulatory pathway involving Notch1/beta-catenin/Isl1 determines cardiac progenitor cell fate
Kwon, C., Qian, L., Cheng, P., Nigam, V., Arnold, J., & Srivastava, D. (2009). A regulatory pathway involving Notch1/beta-catenin/Isl1 determines cardiac progenitor cell fate. NATURE CELL BIOLOGY, 11(8), 951–U96. -
Fibronectin mediates mesendodermal cell fate decisions.
Cheng, P., Andersen, P., Hassel, D., Kaynak, B. L., Limphong, P., Juergensen, L., … Srivastava, D. (2013). Fibronectin mediates mesendodermal cell fate decisions. Development (Cambridge, England), 140(12), 2587–96. -
MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling.
Hassel, D., Cheng, P., White, M. P., Ivey, K. N., Kroll, J., Augustin, H. G., … Srivastava, D. (2012). MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling. Circulation Research, 111(11), 1421–33. -
Notch post-translationally regulates ß-catenin protein in stem and progenitor cells.
Kwon, C., Cheng, P., King, I. N., Andersen, P., Shenje, L., Nigam, V., & Srivastava, D. (2011). Notch post-translationally regulates ß-catenin protein in stem and progenitor cells. Nature Cell Biology, 13(10), 1244–51. -
Reporter-based isolation of induced pluripotent stem cell- and embryonic stem cell-derived cardiac progenitors reveals limited gene expression variance.
van Laake, L. W., Qian, L., Cheng, P., Huang, Y., Hsiao, E. C., Conklin, B. R., & Srivastava, D. (2010). Reporter-based isolation of induced pluripotent stem cell- and embryonic stem cell-derived cardiac progenitors reveals limited gene expression variance. Circulation Research, 107(3), 340–7. -
Coronary Disease Associated Gene TCF21 Inhibits Smooth Muscle Cell Differentiation by Blocking the Myocardin-Serum Response Factor Pathway.
Nagao, M., Lyu, Q., Zhao, Q., Wirka, R. C., Bagga, J., Nguyen, T., … Quertermous, T. (2019). Coronary Disease Associated Gene TCF21 Inhibits Smooth Muscle Cell Differentiation by Blocking the Myocardin-Serum Response Factor Pathway. Circulation Research. -
Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
Zhu, H., Rhee, J.-W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., … Wu, S. M. (2020). Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep, 22(5). -
Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.
Cheng, P., Zhu, H., Witteles, R. M., Wu, J. C., Quertermous, T., Wu, S. M., & Rhee, J.-W. W. (2020). Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Current Cardiology Reports, 22(5), 34. -
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.
Barrett, C. D., Alexander, K. M., Zhao, H., Haddad, F., Cheng, P., Liao, R., … Witteles, R. M. (2020). Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC. Heart Failure. -
Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.
Zhu, H., Rhee, J.-W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., … Wu, S. M. (2020). Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Current Cardiology Reports, 22(5), 36. -
The Environment-Sensing Aryl-Hydrocarbon Receptor Inhibits the Chondrogenic Fate of Modulated Smooth Muscle Cells in Atherosclerotic Lesions.
Kim, J. B., Zhao, Q., Nguyen, T., Pjanic, M., Cheng, P., Wirka, R., … Quertermous, T. (2020). The Environment-Sensing Aryl-Hydrocarbon Receptor Inhibits the Chondrogenic Fate of Modulated Smooth Muscle Cells in Atherosclerotic Lesions. Circulation. -
Molecular mechanisms of coronary disease revealed using quantitative trait loci for TCF21 binding, chromatin accessibility, and chromosomal looping.
Zhao, Q., Dacre, M., Nguyen, T., Pjanic, M., Liu, B., Iyer, D., … Quertermous, T. (2020). Molecular mechanisms of coronary disease revealed using quantitative trait loci for TCF21 binding, chromatin accessibility, and chromosomal looping. Genome Biology, 21(1), 135. -
Single-Cell Transcriptomic Profiling of Vascular Smooth Muscle Cell Phenotype Modulation in Marfan Syndrome Aortic Aneurysm.
Pedroza, A. J., Tashima, Y., Shad, R., Cheng, P., Wirka, R., Churovich, S., … Fischbein, M. P. (2020). Single-Cell Transcriptomic Profiling of Vascular Smooth Muscle Cell Phenotype Modulation in Marfan Syndrome Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, ATVBAHA120314670. -
Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study.
Perino, A. C., Gummidipundi, S. E., Lee, J., Hedlin, H., Garcia, A., Ferris, T., … Perez, M. V. (2021). Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. Circulation. Arrhythmia and Electrophysiology, CIRCEP121010063. -
Ibrutinib-associated atrial fibrillation treatment with catheter ablation.
Kapoor, R., Fazal, M., Cheng, P., Witteles, R., Rhee, J.-W., & Baykaner, T. (2021). Ibrutinib-associated atrial fibrillation treatment with catheter ablation. HeartRhythm Case Reports, 7(11), 713–716. -
ZEB2 Shapes the Epigenetic Landscape of Atherosclerosis.
Cheng, P., Wirka, R. C., Clarke, L. S., Zhao, Q., Kundu, R., Nguyen, T., … Quertermous, T. (2022). ZEB2 Shapes the Epigenetic Landscape of Atherosclerosis. Circulation. -
Arrhythmia Patterns in Patients on Ibrutinib.
Fazal, M., Kapoor, R., Cheng, P., Rogers, A. J., Narayan, S. M., Wang, P., … Rhee, J.-W. (1800). Arrhythmia Patterns in Patients on Ibrutinib. Frontiers in Cardiovascular Medicine, 8, 792310. -
High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning.
Duffy, G., Cheng, P. P., Yuan, N., He, B., Kwan, A. C., Shun-Shin, M. J., … Ouyang, D. (2022). High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiology. -
ZEB2 Shapes the Epigenetic Landscape of Atherosclerosis
Cheng, P., Wirka, R. C., Clarke, L. S., Zhao, Q., Kundu, R., Nguyen, T., … Quertermous, T. (2022). ZEB2 Shapes the Epigenetic Landscape of Atherosclerosis. Circulation, 145(6). -
Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self.
Roy Chowdhury, R., D'Addabbo, J., Huang, X., Veizades, S., Sasagawa, K., Louis, D. M., … Nguyen, P. K. (2022). Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self. Circulation Research, 101161CIRCRESAHA121320090. -
Effective Sphygmomanometer Based Non-invasive Central Venous Pressure Measurement In Hospitalized Heart Failure Patients
Kawana, M., Cheng, P., Morimoto, H., & Fowler, M. (2022). Effective Sphygmomanometer Based Non-invasive Central Venous Pressure Measurement In Hospitalized Heart Failure Patients. JOURNAL OF CARDIAC FAILURE. CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS. -
Embryologic Origin Influences Smooth Muscle Cell Phenotypic Modulation Signatures in Murine Marfan Syndrome Aortic Aneurysm.
Pedroza, A. J., Dalal, A. R., Shad, R., Yokoyama, N., Nakamura, K., Cheng, P., … Fischbein, M. P. (2022). Embryologic Origin Influences Smooth Muscle Cell Phenotypic Modulation Signatures in Murine Marfan Syndrome Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 101161ATVBAHA122317381. -
von Willebrand Factor Is Produced Exclusively by Endothelium, Not Neointima, in Occlusive Vascular Lesions in Both Pulmonary Hypertension and Atherosclerosis.
Steffes, L. C., Cheng, P., Quertermous, T., & Kumar, M. E. (2022). von Willebrand Factor Is Produced Exclusively by Endothelium, Not Neointima, in Occlusive Vascular Lesions in Both Pulmonary Hypertension and Atherosclerosis. Circulation, 146(5), 429–431. -
Artificial intelligence applications in cardio-oncology: Leveraging high dimensional cardiovascular data.
Chen, H., Ouyang, D., Baykaner, T., Jamal, F., Cheng, P., & Rhee, J.-W. (2022). Artificial intelligence applications in cardio-oncology: Leveraging high dimensional cardiovascular data. Frontiers in Cardiovascular Medicine, 9, 941148. -
Smad3 regulates smooth muscle cell fate and mediates adverse remodeling and calcification of the atherosclerotic plaque.
Cheng, P., Wirka, R. C., Kim, J. B., Kim, H.-J. J., Nguyen, T., Kundu, R., … Quertermous, T. (2022). Smad3 regulates smooth muscle cell fate and mediates adverse remodeling and calcification of the atherosclerotic plaque. Nature Cardiovascular Research, 1(4), 322–333. -
Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature.
Fazal, M., Wei, C., Chuy, K. L., Hussain, K., Gomez, S. E., Ba, S. S., … Baykaner, T. (2022). Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature. Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing. -
Molecular mechanisms of coronary artery disease risk at the PDGFD locus.
Kim, H.-J., Cheng, P., Travisano, S., Weldy, C., Monteiro, J. P., Kundu, R., … Quertermous, T. (2023). Molecular mechanisms of coronary artery disease risk at the PDGFD locus. Nature Communications, 14(1), 847. -
Discovery of Transacting Long Noncoding RNAs That Regulate Smooth Muscle Cell Phenotype.
Shi, H., Nguyen, T., Zhao, Q., Cheng, P., Sharma, D., Kim, H.-J. J., … Quertermous, T. (2023). Discovery of Transacting Long Noncoding RNAs That Regulate Smooth Muscle Cell Phenotype. Circulation Research. -
Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.
Wei, C., Fazal, M., Loh, A., Kapoor, R., Gomez, S. E., Shah, S., … Baykaner, T. (2023). Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors. Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing. -
Early clinical outcomes and molecular smooth muscle cell phenotyping using a prophylactic aortic arch replacement strategy in Loeys-Dietz syndrome.
Pedroza, A. J., Cheng, P., Dalal, A. R., Baeumler, K., Kino, A., Tognozzi, E., … Fischbein, M. P. (2023). Early clinical outcomes and molecular smooth muscle cell phenotyping using a prophylactic aortic arch replacement strategy in Loeys-Dietz syndrome. The Journal of Thoracic and Cardiovascular Surgery. -
Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series
Franquiz, M., Waliany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., … Zhu, H. (2023). Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series. JACC: CardioOncology, 839–841. -
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine. -
Comprehensive Integration of Multiple Single-Cell Transcriptomic Datasets Defines Distinct Cell Populations and Their Phenotypic Changes in Murine Atherosclerosis.
Sharma, D., DeForest Worssam, M., Pedroza, A. J., Dalal, A. R., Alemany, H., Kim, H.-J. J., … Quertermous, T. (2023). Comprehensive Integration of Multiple Single-Cell Transcriptomic Datasets Defines Distinct Cell Populations and Their Phenotypic Changes in Murine Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. -
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine, 25(12), 715–735. -
Genome-Wide Genetic Associations Prioritize Evaluation of Causal Mechanisms of Atherosclerotic Disease Risk.
Quertermous, T., Li, D. Y., Weldy, C. S., Ramste, M., Sharma, D., Monteiro, J. P., … Cheng, P. (2024). Genome-Wide Genetic Associations Prioritize Evaluation of Causal Mechanisms of Atherosclerotic Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(2), 323–327.
Practice Locations
General Cardiology at Boswell Building Stanford, CA
Stanford, CA
General Cardiology at Boswell Building
300 Pasteur Drive , 2nd Floor, Room A260
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(12 reviews)
Dr Paul is very kind and personable. He listens well and provides very good advice! I love having Dr Paul as my cardiologist!!
Nice talking to you and provide me lit of information about me and my medication.
Knowledgeable, Professional, courteous,& punctual
Answers all my questions!
Dr. Cheng was extremely helpful and answered all of my questions and concerns. I am grateful for "preventative" care.
Dr. Cheng is welcoming, listens, answers in a language easily understood, and is encouraging.
Thank you to everyone who participated in my first visit today I felt blessed and cared for
Thank you Dr. Paul Cheng!
He was excellent and I really liked him. I felt he gave me a lot of time. Looking forward to seeing him again.
Excellent
Very through. Good bedside manner.
He is very personable, thorough, and courteous.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records